Technology Bundle ID
TAB-2640
Real-time PCR Assays for Selective Detection and Differentiation of B. pertussis, B. parapertussis and B. homesii
Applications
Diagnostics
Linked ID
E-193-2013-0
Lead Inventors
Kathleen Tatti (CDC)
Co-Inventors
Kansas Sparks (CDC)
Maria-Lucia Tondella (CDC)
Development Status
- Early-stage
- In vitro data available
Therapeutic Areas
Infectious Disease
ICs
CDC
CDC researchers developed a real-time PCR assay targeting insertion sequence (IS481) and pertussis toxin subunit 1 (ptxS1) of Bordetella pertussis. This real-time nucleic acid assay offers rapid, sensitive, and quantitative results. The employed primers have been validated through extensive diagnostic testing of 41 Bordetella and 64 non-Bordetella clinical isolates. This technology can be used to diagnose and distinguish B. pertussis, B. parapertussis and B. homesii, the three most common Bordetella human upper respiratory pathogens. A standalone assay or multi-faceted kit may be used.
Commercial Applications
- Diagnostics for Bordetella pathogens
- Investigation of acute upper respiratory illness and outbreaks
Competitive Advantages
- Validated for the three major pathogens responsible for Bordetella-related upper respiratory infections
- Rapid, sensitive and quantitative
- Easily adapted to kit form
- Useful as an added, internal control for present Bordetella pertussis diagnostics
Request More Info
Licensing Contact: